Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2962 in MDS and CMML
NCT07064122Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of azd2962 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by AstraZeneca. Primary endpoints: Number of participants with dose limiting toxicity at 28 days, Number of participants with Adverse events and serious AEs at 3 years and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
azd2962
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT07064122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064122.